| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 432,113 | - | ||
| Sales and marketing | 45,285 | 68,834 | ||
| Research and development | - | 381,061 | ||
| General and administrative | 893,305 | 851,195 | ||
| Total operating expenses | 1,370,703 | 1,301,090 | ||
| Operating loss | -1,370,703 | -1,301,090 | ||
| Changes in fair value of warrant liability | - | 62,112 | ||
| Other income (expense) | 42,018 | 13,066 | ||
| Changes in fair value of warrant liability | 267,274 | - | ||
| Total other expenses | - | 75,178 | ||
| Total other income (expenses) | -225,256 | - | ||
| Loss from operations before income taxes | -1,595,959 | -1,225,912 | ||
| Provision for income taxes | - | 0 | ||
| Net loss | -1,595,959 | -1,225,912 | ||
| Net loss per share basic and diluted (in dollars per share) | -2.1 | - | ||
| Net loss per share diluted (in dollars per share) | -2.1 | - | ||
| Weighted average common shares basic and diluted (in shares) | 761,218 | - | ||
| Weighted average common shares diluted (in shares) | 761,218 | - | ||
ENDRA Life Sciences Inc. (NDRA)
ENDRA Life Sciences Inc. (NDRA)